PMXstan: An R Library to Facilitate PKPD Modeling with Stan (abstract)
M-002
David Tenero
Tafenoquine (TQ; SB252263) Population Pharmacokinetic (PK) Model and Efficacious Dose Simulation in Plasmodium vivax Malaria Subjects (abstract)
M-003
L. Li
Systematic Comparison of Approaches to Handle Below Quantification Limit Data in Population Pharmacokinetic Analyses (abstract)
M-004
Aniruddha Amrite
Sequential Population PK-Viral Dynamic Modeling of TD-6450, a Next Generation Once Daily NS5A Inhibitor, following 3-Day Monotherapy in Patients with GT-1 HCV Infection (abstract)
M-005
Gilbert Koch
Fabry Disease Progression with and without Enzyme Replacement Therapy (abstract)
M-006
Elliot Offman
Population Physiologically-Based Pharmacokinetic Model Incorporating Lymphatic Uptake for a Subcutaneously Administered Pegylated Peptide (abstract)
M-007
Meihua R. Feng
Population Pharmacokinetics of Mycophenolic Acid and its Glucuronide Metabolite in Lung Transplant Recipients with and without Cystic Fibrosis(abstract)
M-008
Jean Lavigne
Modeling and Simulation of Piperaquine (PQ) After Administration of Eurartesim® (PQ Tetraphosphate/Dihydroartemisinin)(abstract)
M-009
Dan Lu
Time-to-event analysis of polatuzumab vedotin induced peripheral neuropathy to assist comparison of dosing regimen (abstract)
M-010
Lisa O’Brien
Population Pharmacokinetic Meta-Analysis of Ramucirumab in Cancer Patients(abstract)
M-011
Tomoko Freshwater
Assessment of Pembrolizumab (MK-3475) Dosing Strategy Based on Population Pharmacokinetics and Exposure-Response Models (abstract)
M-012
Ying Hong
Model-Based Approach for Dose Optimization of HSP90 Inhibitor Luminespib(abstract)
M-013
Julie Pasarell
Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults(abstract)
M-014
Vijay Ivaturi
CLIP: The Command-Line Interface to Phoenix NLME(abstract)
M-015
A. Corey
Prediction of Anthrax Toxin Protective Antigen Kinetics in Humans(abstract)
M-016
Ho-Pi Lin
Combination of R “Shiny” and Application Programming Interface (API) to Create a Browser Based Visualization Tool for FDA Public Database(abstract)
M-018
Michael J. Reed
A Quantitative Systems Pharmacology Platform to Investigate the Impact of Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics: Insights for the Clinical Application of PCSK9 Inhibitors (abstract)
M-019
Roberto Gomeni
Modeling Complex PK Profiles of Long Acting Injectable Products Using a Convolution-Based Approach (abstract)
M-020
Ophelia Yin
Longitudinal Exposure-Response Relationship for Mirogabalin in Patients with Diabetic Peripheral Neuropathic Pain (abstract)
M-021
Phyllis Chan
Nonlinear Mixed Effects Modeling of Disease Progression of Placebo Subjects from the Irbesartan Diabetic Nephropathy Trial(abstract)
M-022
Yasong Lu
Model-Based Meta-Analyses (MBMA) of DAS28 Reduction in Support of Rheumatoid Arthritis Development Programs(abstract)
M-023
Qi Wang
Development of a Physiologically Based Pharmacokinetic Model for Daclastavir and Prediction of Drug-Drug Interactions with P-gp and CYP3A4 Inhibitors(abstract)
M-024
David Z. D’Argenio
Feedback Control Indirect Response Models(abstract)
M-025
Kyunghee Yang
Mechanistic Modeling with DILIsym® Predicts Dose-Dependent Clincial Hepatotoxicity of AMG 009 That Involves Bile Acid (BA) Transporter Inhibition(abstract)
M-026
Linzhong Li
Evaluating the Efficiency of Payload Delivery by ADCs Using a Minimal PBPK Model(abstract)
M-027
Brian J. Schmidt
Development of a Quantitative Systems Pharmacology (QSP) Platform to Support Translational Research and Clinical Development in Immuno-Oncology(abstract)
M-028
Emilie Schindler
Analyzing Patient-Reported Outcomes in Breast Cancer through Item-Response Theory Pharmacometric Modeling(abstract)
M-029
Denison J. Kuruvilla
A Method to EvaluateFetal Erythropoiesis from Postnatal Survival of Fetal RBCs(abstract)
M-030
Stephen Duffull
An Approximation to the Solution of Systems of Nonlinear Ordinary Differential Equations in Pharmacokinetics-Pharmacodynamics(abstract)
M-031
Eric G. Burroughs
Immuno-Viral Dynamics Modeling of Letermovir for Treatment of Human Cytomegalovirus (HCMV) Infection in Post-Transplant Settings(abstract)
M-032
Owen JS
Pharmacogenetic-Based Pharmacokinetic Modeling of Plasma and Intracellular Concentrations of Efavirenz on Adult Ethiopian HIV and TB/HIV Patients(abstract)
M-033
Hugo Geerts
From Big Data to Smart Data. How Quantitative Systems Pharmacology Can Support CNS Pharmaceutical R&D(abstract)
M-034
D. Zhang
Implementation of Non-linear Mixed Effect Modeling Approach in Allometric Scaling For Human Clearance Prediction(abstract)
M-035
Xiao Hu
Prediction of Pharmacokinetic Profiles of an Anti-TWEAK Monoclonal Antibody, BIIB023, in Pediatric patients with Lupus Nephritis (abstract)
M-036
Hyewon Kim
Exploration of Model-Based Bioequivalence (BE) Evaluation as an Alternative Approach for the Sparse Pharmacokinetic (PK) Sampling Design
M-037
Sebastian Ueckert
Evaluation of the Expected Fisher Information Matrix without Linearization, in Nonlinear Mixed Effect Models for Discrete and Continuous Outcomes (abstract)
M-038
Shuhua Hu
Implementation of a highly nonlinear, multi-scaled and long-term HIV dynamic model with treatment interruptions and non-static BQL data for population analysis(abstract)
M-039
Heather E. Vezina
Ipilimumab Exposure-Response (E-R) Analysis of Overall Survival (OS) in Patients with Advanced Melanoma(abstract)
M-040
Yanhui Lu
Translational Modeling of Regular Human Insulin Pharmacokinetics and Glucose Dynamics in Minipigs(abstract)
M-041
In-Jin Jang
Population Pharmacokinetic Analysis of Once Daily Formulation of Tacrolimus in Kidney Transplantation Patients(abstract)
M-042
Steven W. Martin
Mechanistic Population Pharmacokinetics Model of PF-00547659, a Full Human lgG2 anti-MAdCAM Monoclonal Antibody in Ulcerative Colitis Patients(abstract)
M-043
Nagdeep Giri
Population Pharmacokinetic Model (PopPK) for Dacomitinib and its Metabolite in Healthy Volunteers (HV) and Patients with Advanced Solid Tumors(abstract)
M-044
Kenta Kadotsuji
Quantitative Approach to Predicting Human Pharmacokinetics of Monoclonal Antibody (DSP-mAbX) from Preclinical Data(abstract)
M-045
Anasuya Hazra
Quantitative Assessment of the Exposure- Response Relationships of PF00547659, a Full Human IgG2 anti-MAdCAM Monoclonal Antibody, as Induction Therapy for Ulcerative Colitis in a Phase 2 Study(abstract)
M-046
Mahesh N. Samtani
8-Year Disease Progression in Asymptomatic at Risk for Alzheimer Dementia (ARAD) Subjects from ADNI-1(abstract)
M-047
Renu Singh
Pharmacokinetic/pharmacodynamic (PK/PD) Characteristics of Veliparib with and without Temozolomide in Patients with Hematological Malignancies(abstract)
M-048
Woodhead JL
Quantitative Systems Modeling Provides Biological Plausibility for Potential Mechanisms of Tolvaptan-Induced Hepatotoxicity(abstract)
M-049
April M. Barbour
Application of Complementary Statistical and Modeling Analyses to Identify Predictors of Sustained Virologic Response in Patients with Chronic Hepatitis C (abstract)
M-050
M. Craig
The Robust Response of a Physiological Model of Granulopoiesis to PK Variability(abstract)
M-051
Karen Schneck
Mechanistic Model based Assessment of PK/PD Critical Success Factors (CSF) for Next-Generation Ultra-fast Acting Insulins (abstract)
M-052
Malidi Ahamadi
Pooled Population Pharmacokinetic and Immunogenicity Analysis of Pembrolizumab Using Data from KEYNOTE-001, KEYNOTE-002 and KEYNOTE-006(abstract)
M-053
Ben G Small
Repolarisation Rate: An Integrative Biomarker of cCardiac Action Potential Repolarisation(abstract)
M-054
Dong-Seok Yim
Overestimation of Shape Parameter of Weibull Base Hazard in the Modeling of Time-To-Event Data(abstract)
M-055
Olivier Barrière
inVentR: The Pharmacometrician’s Best Friend(abstract)
M-056
Mélanie Wilbaux
Semi-Mechanistic Model to Predict In-Hospital Natural Weight Changes in Term Neonates(abstract)
M-057
Satyendra Suryawanshi
Leveraging Longitudinal Tumor Data for Prediction of Overall Survival from I-O therapy: A Proof of Concept with Quantitative Models and External Validation(abstract)
M-058
Gaurav Bajaj
Characterization of the Pharmacokinetics and Exposure-Response Relationship for Nivolumab in Patients with Previously Treated or Untreated Advanced Melanoma(abstract)
M-059
Renu Singh
Comparison of Different Methods for Predicting Pharmacokinetics of Monoclonal Antibodies in Human(abstract)
M-060
Timothy J Carrothers
PKPD Modeling of Vilazodone (VLZ) in Adult Patients with Generalized Anxiety Disorder (GAD)(abstract)
M-061
Xiaoning Wang
Characterizing Exposure-Response (E-R) Relationship of Safety for Nivolumab in Combination with Ipilimumab in Patients with Previously Untreated Advanced Melanoma(abstract)
M-062
Kimberley Jackson
A PKPD Model Describing the Effect of Ixekizumab on Absolute Psoriasis Area and Severity Index (PASI) score in Patients with Moderate to Severe Plaque Psoriasis (abstract)
M-063
Craig J. Thalhauser
Mechanistic Predictions of Response to Combinations of Biologic Agents in a Quantitative Systems Pharmacology Model of Rheumatoid Arthritis(abstract)
M-064
Christina M. Friedrich
Model Qualification Approaches for Quantitative Systems Pharmacology and Mechanistic Physiological Modelsabstract
M-065
J.S. Macwan
Physiologically Based Pharmacokinetic Modeling of Rosuvastatin and Prediction of Transporter-Mediated Drug-Drug Interactions Involving Gemfibrozil(abstract)
M-066
John Harrold
A General Method for Initialization of Steady-States in Complex PK/PD Systems(abstract)
M-067
Sihem Ait-Oudhia
In Vivo Mechanisms of Drug-load Release for Antibody Drug Conjugates and Their Relationships To Drug-Related Toxicity(abstract)
M-068
C. Passey
Model-Based Analysis to Support Clinical Pharmacology Profiling of Elotuzumab in Patients with Multiple Myeloma(abstract)
M-069
France Mentré
Bayesian Fisher Information Matrix for Predicting Estimation Error and Shrinkage of Individual Parameters with Data Below the Quantification Limit(abstract)
M-070
France Mentré
Optimal Design for Informative Protocols in Xenograft Tumor Growth Inhibition Models (abstract)
Tuesday
T-001
Xiaohua Gong
A Compartmental Epidemic and Outcome Model Framework with User-Friendly Interactive Inputs and Dynamic Outputs(abstract)
T-002
Yuan Xiong
Non-Homogeneous Poisson Process (NHPP) Analysis of Time to First Flare for Canakinumab (CAN) Dose Justification in SJIA(abstract)
T-003
Harish Shankaran
A Mechanism-Based Translational Mathematical Model for Gastrointestinal Toxicity(abstract)
T-004
Scott Van Wart
Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling of Tolvaptan and Diuretic Use on Fluid and Electrolyte Balance in Healthy Subjects(abstract)
T-005
Karen Schneck
Enhancing Clinical Utility of Model-based Pharmacokinetic Profiles of Subcutaneous Insulin Through Interactive Visualization(abstract)
T-006
Seung-Wook Chung
Systems Pharmacology Modeling and Analysis of Therapeutic Antibodies Antagonizing IL13-Mediated Disease Signaling(abstract)
T-007
Johannes Schropp
Uncompetitive and Competitive Drug-Drug Interaction with Target-Mediated Drug Disposition(abstract)
T-008
Daniel Gonzalez
Population Pharmacokinetics of Morphine in Patients with Non-Alcoholic Steatohepatitis (NASH) and Healthy Adults(abstract)
T-009
Xiaosu Ma1
Simulation-Based Assessment of Insulin Lispro Dose Titration Algorithms Using a Model of Glucose-Insulin-Glucagon Dynamics(abstract)
T-010
Alanna McEneny-King
Web Accessible Population Pharmacokinetics Service – Hemophilia (WAPPS-Hemo): A Service for Bayesian Post Hoc Estimation(abstract)
T-011
Murad Melhem
Quantitative Characterization of the Effects of Acute Radiation (AR) and Treatment with Filgrastim (Neupogen) on Absolute Neutrophil Counts (ANC) and Overall Survival (OS) in Non-Human Primates (NHP) (abstract)
T-012
Craig Fancourt
Development of a Joint PKPD Model of the Hyperinsulinemic Glucose Clamp(abstract)
T-013
Harvey, Jay
Relationship Between Eslicarbazepine Exposure and Efficacy of Eslicarbazepine Acetate Adjunctive Therapy(abstract)
T-014
Alexander C. Ross
A Method for Simulating Dopamine Agonist Self-Administration with a Receptor-Based Mechanism(abstract)
T-015
Joel M. Reid
Population Pharmacokinetic Model for Oral Endoxifen in Patients with Breast or Gynecologic Cancers(abstract)
T-016
A. Corey
Simulated Implications of Predicted PA Kinetics in Humans for Treatment of Inhalational Anthrax(abstract)
T-017
Sameer Doshi
Effect of Clinical Study Design on Estimation of Pharmacokinetic Parameters in Pediatric Populations Using Pharmacokinetic Parameters from Adult Populations as Bayesian Priors: Application to Target Mediated Drug Disposition Models (TMDD)(abstract)
T-018
Lora Hamuro
Prediction of Human Immunogenicity for a Biotherapeutic Candidate Using a Mechanistic Model of the Immune System(abstract)
T-019
Feng Jin
Exposure-Response of Idelalisib, a Novel PI3Kδ Inhibitor, in the Combination Therapy of Chronic Lymphocytic Leukemia (abstract)
T-020
Liviawati S Wu
The Impact of Ribavirin Plasma and Cellular Pharmacokinetics and Host Genetics on Anemia and Antiviral Response to Hepatitis C Treatment (abstract)
T-021
In-Jin Jang
Population Pharmacokinetics of Tarolimus in Pediatric Renal Transplant Recipients on Two Different Formulations - Twice-daily Prograf® and Once-daily Advagraf®(abstract)
T-022
Mirjam N. Trame
tVPC: A User-Friendly Matlab-based Tool for the Evaluation and Simulation of Systems Pharmacology Models(abstract)
T-023
Nan Zheng
Assessment of Partial AUC Requirement for Bioequivalence Evaluation of Methylphenidate Hydrochloride Extended-Release Oral Suspension(abstract)
T-024
Benjamin Guiastrennec
Quantitative Model Diagrams (QMD): A New Perspective in Model Evaluation(abstract)
T-025
Weirong Wang
Aqueous Humor VEGF Suppression and Clinical Efficacy of VEGF-targeting Biologics in Age-related Macular Degeneration(abstract)
T-026
Malek F. Okour
Comparative Evaluation of Bias And Precision in Compartmental Models of Enterohepatic Circulation (abstract)
T-027
Dooyeon Jang
Interpretation of Drug-Drug Interaction Study Results of Long Elimination Half-Life Drugs: Comparison of Conventional Bioequivalence Test Anda Model-Based Approach(abstract)
T-028
Mélanie Wilbaux
Semi-Mechanistic Model to Characterize Effects of Gastric Emptying on Glucose Absorption in Obese and Non-Obese Adults(abstract)
T-029
Geraldine Celliere
Towards Improving In Vitro–In Vivo Toxicity Extrapolation Using Multi-Scale Modeling: A Proof of Concept on Paracetamol Hepatotoxicity (abstract)
T-031
Gilbert Koch1
Delay Differential Equation Solver in ADAPT 5(abstract)
T-032
Julie Autmizguine
Dose-Exposure Simulation for Optimal Piperacillin-Tazobactam Strategy in Infants and Young Children(abstract)
T-033
Sebastian Ueckert
Improved Confidence Intervals and P-Values by Sampling from the Normalized Likelihood (abstract)
T-034
Elodie L. Plan
Handling Underlying Discrete Variables with Mixed Hidden Markov Models in NONMEM(abstract)
T-035
Helen Moore
Mathematical Optimization of Combination Therapy for Chronic Myeloid Leukemia (CML)(abstract)
T-036
Koichiro Yoneyama
Impact of Age on Population Parameter Estimates and Pediatric Prediction Performances of Monoclonal Antibody Clearance: A Simulation Study(abstract)
T-037
Kyung-Sang Yu
Population Pharmacokinetics of Voriconazole in Healthy Korean Male with Various CYP2C19 Genotypes (abstract)
T-038
Manisha Lamba
How Quantitative Modeling of a Biomarker was Leveraged in Understanding Pharmacodynamic Recovery: An Illustration using Changes in Natural Killer Cells with Tofacitinib
T-039
Shuhua Hu
A Distributed Delay Approach for Modeling Delayed Outcomes in Pharmacokinetics and Pharmacodynamics Studies(abstract)
Evaluating the Performance of Different Expectation Maximization Algorithms in Handling Complex Pharmacometric Models
T-042
Dana Nickens
Exposure-Response Analsysis of Efficacy and Safety Endpoints for Crizotinib in the Treatment of Patients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC)(abstract)
T-043
Zheng Jiao
The Effect of Poor Compliance on the Pharmacokinetics of Valproic Acid in Children with Epilepsy Using Monte Carlo Simulation(abstract)
T-044
Iñaki F. Trocóniz
Towards Patient Stratification in Systemic Lupus Erythematosus using a Systems Pharmacology Approach(abstract)
T-045
Rukmini Kumar
Estimating Parameters by Optimization Algorithms in a Simple PK Model with Bifurcations (abstract)
T-046
Maciej J Swat
Pharmacometric Markup Language (PharmML) & Standardised Output (SO) - Encoding Standards for Exchange of Models and Results in Pharmacometrics and Quantitative Systems Pharmacology(abstract)
T-047
Jakob Ribbing
Predicting Reductions in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations from FEV1 – A Model-Based Meta-Analysis of Literature Data from Controlled Randomized Clinical Trials(abstract)
T-048
Timothy Bergsma
Implementing FDA Specifications in R for Submission of Analysis Datasets(abstract)
T-049
Bojan Lalovic
PK-PD Analysis of PASI with Data at Boundary: BI 655066 an Anti-IL-23A mAb for the Treatment of Psoriasis(abstract)
T-050
Rik Schoemaker
Modeling the Effect of Levetiracetam on Daily and Aggregated Seizure Counts in Adults and Children
T-051
William S. Denney
Simple, Automatic Noncompartmental Analysis: The PKNCA R Package(abstract)
T-052
Daniela J Conrado
Facilitating Exposure-Response Analysis of Cardiovascular Safety Markers in Early-Phase Clinical Studies with the cardioModel Package for R(abstract)
T-053
Malidi Ahamadi
Model-Based Pooled Analysis of Exposure and Safety of Pembrolizumab with Advanced Melanoma and Non-Small Cell Lung Carcinoma (NSCLC)(abstract)
T-054
Jürgen B. Bulitta
Enterohepatic Recirculation and Gender Differences of Roxithromycin in Humans Assessed via Population Pharmacokinetics(abstract)
T-055
Brian J. Schmidt
Development of a Quantitative Systems Pharmacology (QSP) Platform to Support Translational Research and Clinical Development of Affinity Drug Conjugates (ADCs)(abstract)
T-056
Yan Feng
Exposure-Response (E-R) Analysis of Progression Free Survival (PFS) for Nivolumab in Combination with Ipilimumab in Patients with Previously Untreated Advanced Melanoma(abstract)
T-057
Karim Azer
Enhancing the Utility of Systems Pharmacology Modeling in Pharmaceutical R&D: Lessons from the development of a PCSK9 Inhibitor Model(abstract)
T-058
Vijay Ivaturi
Population Pharmacokinetics of Sorafenib in Acute Myelogenous/B-Type Leukemia Patients(abstract)
T-059
Devin Pastoor
Extending Rstudio's Functionality to Accelerate Modeler Workflows via Shiny Applications(abstract)
T-060
Sharon Karan
Population PK/PD from a Phase I Study of the Single-Agent PARP Inhibitor, Veliparib, in Patients with PARP Sensitive Tumor Types or BRCA 1/2 –Mutated Cancer(abstract)
T-061
Timothy J Carrothers
Population Pharmacokinetic (PPK) Modeling of Vilazodone in Adolescent Patients with Major Depressive Disorder (MDD)(abstract)
T-062
Mohamad-Samer Mouksassi
GGplot-Shiny: A Shiny App That Facilitates Data Manipulation And Exploration(abstract)
T-063
Jinzhong Liu
SASR (Survival Analysis using “Shiny” R): A Browser Based Survival Analysis Visualization Tool using R “Shiny”(abstract)
T-064
Emmanuel Chigutsa
The Effect of Body Weight on Necitumumab Pharmacokinetics and Pharmacodynamics in Patients with Squamous Non-Small Cell Lung Cancer: Dosing Implications(abstract)
T-065
C. Passey
Latent Variable Approach to Assess the Time-Varying Effect of Immunogenicity on the Pharmacokinetics of Elotuzumab in Patients with Multiple Myeloma(abstract)
T-066
Chih-Wei Lin
Population Pharmacokinetics of ABT-493 in HCV Genotype 1 Infected Subjects with or without Cirrhosis in Three-Day Monotherapy Study(abstract)
T-067
Janelle Hajjar
Trends in the Application of Pharmacometric Modeling and Simulation in the Development of Orphan Drugs in the 21st Century(abstract)
T-068
D. Zhang
Letermovir Exposure is Similar in HSCT Patients and Healthy Volunteers (abstract)
T-069
Chay Ngee Lim
Phxnlme: An R Package that Faciliates Pharmacometrics Workflow of Phoenix NLME Analyses(abstract)
T-070
Eun Kyoung Chung
Comparative Population Pharmacokinetics of Ofloxacin, Ciprofloxacin, Levofloxacin, and Moxifloxacin using Bioequivalence Study Data(abstract)
Wednesday
W-001
Da Zhang
Model Based Meta Analysis to Characterize the Dose-Efficacy Profile of Recombinant FSH for Controlled Ovarian Stimulation(abstract)
W-002
Dhananjay Marathe
Utilizing Modeling and Simulation to Inform Dose Selection, Titration Algorithms, and Trial Design of Oral Testosterone (T) Products for Testosterone Replacement therapy (TRT) in Hypogonadal Men(abstract)
W-003
Emmanuel Chigutsa
Population Pharmacokinetics and Pharmacodynamics of an Oral Glucagon Receptor Antagonist (LY2409021) in Patients with Type 2 Diabetes Mellitus(abstract)
W-004
Kristin Dickschen
PBPK Modeling to Guide Experimental Design in Drug Development(abstract)
W-005
Jun Li
Model Based and Model Independent Evaluations of Steady-State Volume of Distribution (Vdss) of Two-Compartment Pharmacokinetic Models with Parallel First-Order and Michaelis-Menten Eliminations(abstract)
W-006
Scott Van Wart
Pharmacokinetic-Pharmacodynamic (PK-PD) Model for Tolvaptan in Patients with Hypervolemic Hyponatremia (abstract)
W-007
Manish R. Sharma
A Disease Progression Model of Castrate Resistant Prostate Cancer (CRPC) Using Prostate Specific Antigen (PSA) (abstract)
W-008
Donald E. Mager
Pharmacodynamic Model of Vorinostat Effects in Multiple Myeloma Cells and Xenografts(abstract)
W-009
Leonid Gibiansky
Target-Mediated Drug Disposition (TMDD) Equations and Approximations for Systems with 1:2 and 2:1 Drug-Target Binding Stoichiometry(abstract)
W-010
Jasper Stevens
Population Pharmacokinetic/Pharmacodynamic Modeling of a Next Generation Recombinant Human Factor VIIa (LR769) to Derive the Dose to be Studied in Phase 3(abstract)
W-011
Ocampo-Pelland AS
Model-Based Meta-Analysis to Develop a Vitamin D Parent-Metabolite Population-Pharmacokinetic Model (abstract)
W-012
Shringi Sharma
Population Pharmacokinetics and Exposure-Response Analysis of Entospletinib, a Selective Spleen Tyrosine Kinase Inhibitor(abstract)
W-013
Eric G. Burroughs
A Model-Based Meta-Analysis of Insulin PK-PD in Glucose Clamp Studies of Diabetes Mellitus Type 1 and Non-Diabetic Human Subjects(abstract)
W-014
Gary Milavetz
Population Pharmacokinetics of Ethanol in Moderate and Heavy Drinkers(abstract)
W-015
Leijun Hu
Population Pharmacokinetics and Pharmacodynamics of Blosozumab(abstract)
W-016
Murad Melhem
Population Pharmacokinetics and Pharmacodynamics (PK/PD) of AMG 416 in Chronic Kidney Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (sHPT) Receiving Hemodialysis(abstract)
W-017
Andrijana Radivojevic
Datasets for Pharmacometric Analyses: Internal Review and Standardization Efforts(abstract)
W-018
Vijay Ivaturi
Pharmacokinetics of Flavopiridol Using Bolus or Hybrid Administration Schedules in the Treatment of Acute Leukemias(abstract)
W-019
Colin Phipps
A PBPK Model Platform for Nanoparticles Including Lymphatic and Size-Dependent Transport(abstract)
W-020
Ludwig EA
Eslicarbazepine Acetate Drug-Drug Interactions: Characterization Through a Model-Based Population Approach(abstract)
W-021
Ignacio Gonzalez-Garcia
Building an Inflammatory Bowel Disease Network, a Systems Pharmacology Approach(abstract)
W-022
Fahima Nekka
Identification and Quantification of Noncompliance Patterns Associated to Specific Clinical Outcomes(abstract)
W-023
Kyle T. Baron
Simulation from ODE-Based Population PK/PD and Systems Pharmacology Models in R with mrgsolve(abstract)
W-024
Wan Sun
Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation of Neutropenia in Patients With Advanced Cancer Treated With Palbociclib(abstract)
W-025
Timothy H Waterhouse
Impact of Model Uncertainty on Phase 2 Diabetes Trial Design (abstract)
W-026
Chih-Wei Lin
Population Pharmacokinetics of a Pangenetic NS5A inhibitor, ABT-530, in HCV infected Patients with and without Cirrhosis(abstract)
W-027
Sébastien Bihorel
Toward Progressive Reporting of Modeling and Simulation Results – Part 1: Analysis of KIWI™ Metadata(abstract)
W-028
Eudy, RJ
Linking a Mechanistic Model of Bone Mineral Density to a Time-to-Event Model to Evaluate Effects of Various Therapies on Fracture Risk in Postmenopausal Women with Osteoporosis(abstract)
W-029
Jason Healy
Development of a Population Pharmacokinetic Model for Vancomycin on an Extracorporeal Membrane Oxygenation (ECMO) Therapy Patient Population(abstract)
W-030
Shuhua Hu
Comparison of Laplacian, Quasi-Random Parametric Expectation Maximization (QRPEM) and Non-parametric Methods for Population Analysis of Complex Dynamic System with Non-static BQL Data(abstract)
W-031
V.Goti
Comparison of Model Based and Model Independent Approaches for Handling Data Below the Limit of Quantitation(abstract)
W-032
Pei Hu
Population PK/PD/Survival Modeling Analysis of Icotinib in Chinese Non-Small Cell Lung Cancer Subjects(abstract)
W-033
Devin Pastoor
Translating Older R Data Manipulation Workflows to the Modern Equivalents(abstract)
W-034
Liang Zhao
Assessment of Exposure-Response (E-R) and Case-Control (C-C) Analyses in Oncology using Simulation Based Approach(abstract)
W-035
Amita Joshi
Survey of Methodologies for Exposure-Response Analysis of Oncology Drugs Approved in FDA from 2010 to 2015(abstract)
W-036
Nageshwar R Budha
Analysis of Exposure-Response Relationships for Cobimetinib in Combination with Vemurafenib(abstract)
W-037
Martin Boucher
Model Based Network Meta-Analysis for Pharmacometrics and Drug-Development: A 3 year Research Collaboration between Pfizer and the University of Bristol(abstract)
W-038
Sebastian Ueckert
Modeling the Neuropsychiatric Inventory (NPI) – Strengths and Weaknesses of a Multidimensional Item Response Theory Approach(abstract)
W-039
Manash S. Chatterjee
Model-Based Analysis of the Relationship between Pembrolizumab Exposure and Response in Melanoma (abstract)
W-040
Mirjam N. Trame
Development of a Non-Human Primate PK/PD Model of a Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus(abstract)
W-041
Thuy Vu
Optimal Design for Pediatric Study of a Monoclonal Antibody Exhibiting Nonlinear PK(abstract)
W-042
Jin Yan Jin
Clinical Trial Simulations to Assess the Probability of Revealing Biomarker Dose-Response in Ph1 Trials(abstract)
W-043
Hartmut Derendorf
Investigating Robustness of Proposed Models to Describe the Novel Mechanism of Atypical Nonlinear Plasma Protein Binding Behavior of Tigecycline(abstract)
W-044
Matts Kågedal
Binning of Exposures in Survival Analysis for Oncology - A Simulation Study(abstract)
W-045
Dan Polhamus
A M&S Framework for Exposure-Response Analysis in Oncology: Comparison and Considerations of Multiple Methodologies(abstract)
W-046
Mathangi Gopalakrishnan
Leveraging Biomarkers, Clinical Endpoints, and Exposure-Response Modeling and Simulation to Optimize Phase 3 Dose Selection(abstract)
W-047
Catherine MT Sherwin
Pharmacokinetic Modeling of Plasma and Salivary Caffeine Circulation in Infants Receiving Extended Caffeine Therapy for Intermittent Hypoxia Treatment(abstract)
W-048
Julie Desrochers
To antidote or not? Population Pharmacokinetic Modeling and Bayesian Forecasting as a Tool to Predict the Need for Antidote in Acute Acetaminophen Overdose (abstract)
W-049
Julie Passarell
Systemization of Logistic Regression Analysis for Pharmacometric Applications(abstract)
W-050
Chetan Rathi
Pharmacokinetic-Pharmacodynamic Analysis of Spectinamide Antibiotic Lee1599 in Mycobacterium tuberculosis Infected Mice(abstract)
W-051
Jeannine Fisher
Effect of Trial Design on Exposure-Response (E-R) Analyses in Rare Diseases: A Simulation Case Study in Duchenne Muscular Dystrophy (DMD) with the 6-Minute-Walk-Test-Distance (6MWTD) Endpoint(abstract)
W-052
Josiah T. Ryman
Modeling the Impact of Antidrug Antibody Formation on the Pharmacokinetics of a Fully Human Monoclonal Antibody in a Preclinical Rodent Model(abstract)
W-053
Jian Xu
Development of a Mega Population Pharmacokinetic (PK) Model of an Antibody-Drug Conjugate (ADC) Platform(abstract)
W-054
Bhargava Kandala
A Dynamic Model-Based Analysis of a Multi-Level Glycemic Clamp Study of Regular Human Insulin in T1DM Subjects(abstract)
W-055
John Zhu
Development of a Plasma/Dermis Population Pharmacokinetic Model for GSK1940029(abstract)
W-056
Ludivine Fronton
Getting Clear on Non-Specific Tissue Clearance of mAbs: Insights from PBPK Modeling(abstract)
W-057
Jürgen Bulitta
Novel Mechanism-based Population Pharmacokinetic/Pharmacodynamic Model of Blood Pressure and the Antihypertensive Activity of Fimasartan(abstract)
W-058
Kenneth Luu
Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Modeling and Covariate Analysis for ISIS GCGRRx (449884), a Second Generation Antisense Oligonucleotide Glucagon Receptor (GCGR) Inhibitor for the Treatment of Type 2 Diabetes Mellitus(abstract)
W-059
John Harrold
Cell-Level Model of Pharmacodynamics-Mediated Drug Disposition: Application to Filgrastim (Neupogen)(abstract)
W-060
Francois Gaudreault
Assessment of CYP3A-Mediated Drug-Drug-Interaction Potential for PF-X in Healthy Subjects:
W-061
Weirong Wang
Minimal Physiologically-Based Pharmacokinetic (mPBPK) Model for a Monoclonal Antibody (mAb) against Interleukin-6 in Mice with Collagen-Induced Arthritis (CIA)(abstract)
W-062
Ferdous Gheyas
Pharmacokinetic and Pharmacokinetic / Pharmacodynamic Modeling to Inform Optimal Dose of Vorapaxar (abstract)
W-063
Loveleena Bansal
Development of a Quantitative Systems Pharmacology (QSP) Model of Psoriasis: Overview and Challenges (abstract)
W-064
Phyllis Chan
Population Pharmacokinetic and Pharmacodynamic Analyses of Entecavir in Pediatric Subjects
W-065
Wei Gao
Viral Dynamics Modeling of MK-3682 Monotherapy in HCV-infected Patients (abstract)
W-066
Beesan Tan
Translational PK-PD-Viral Dynamics (VD) Modeling: An Application in Respiratory Syncytial Virus (RSV) Program(abstract)
W-067
Scott Marshall
Application of Model Informed Drug Discovery and Development (MID3) to Gout(abstract)
W-068
D. Zhang
Nonlinear Pharmacokinetics of Letermovir in Phase 1 Suggest a Role of Induction (abstract)
W-069
Wangda Zhou
Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Children (abstract)
W-070
Seong-heon Lee
Population Pharmacokinetic and Pharmacodynamic Modeling of Ramosetron for the Prophylaxis of Postoperative Nausea and Vomiting(abstract)
W-071
John C. Lukas
Use of Pharmacokinetic and Pharmacodynamic Knowledge of Bilastine for the Optimal Design of the First Pediatric Trial(abstract)
